Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q3 2022 · 10-Q
Revenue$59.22M$59.22M−0.8% vs Q3 2021 Net Income$404.00K$404.00K−97.1% vs Q3 2021 EPS Diluted$0.02$0.02−97.5% vs Q3 2021 Operating Income$12,341,000−21.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$16,160,000−11.5% Margins · derivedOperating margin20.8%−5.5 pt vs Q3 2021
Net margin0.7%−22.3 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end